A.C. Simmonds And Sons Acquires Position In Cardiogenics Holdings Inc.
ACCESSWIRE - Tue Nov 17, 7:55AM CST
TORONTO, ON / ACCESSWIRE / November 17, 2015 / A.C. Simmonds and Sons Inc., (OTCPK:ACSX) announced today it has acquired, through a transfer of shares and assumption of debt, an equity position in CardioGenics Holdings Inc. A.C. Simmonds and Sons agreed to acquire a convertible debenture in the amount of $10,000,000 CDN (Ten Million Canadian Dollars) of CardioGenics Holdings Inc. (OTCQB:CGNH) and 15,000,000 common shares of CGNH and 10,000,000 cashless warrants at a strike price of $0.50 USD.
CardioGenics Enters Into Asset Purchase Agreement to Acquire All Assets of Ontario-Based Plasticap
Marketwired - Wed Nov 04, 12:46PM CST
CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD"
CardioGenics Enters Into Binding Letter of Intent to Acquire Assets of Ontario-Based Plasticap
Marketwired - Mon Oct 05, 8:01AM CDT
CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD"
CardioGenics Enters Into Manufacturing Agreement With Ontario-Based Plasticap
Marketwired - Tue Aug 25, 8:02AM CDT
CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD"
USPTO Issues Notice of Allowance in Connection With CardioGenics' Self-Metering Cartridge Patent Application
GlobeNewswire - Tue Feb 17, 8:50AM CST
CardioGenics Holdings Inc. (OTCQB:CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD"
CardioGenics Announces Appointment of New Director
GlobeNewswire - Mon Jan 12, 3:30PM CST
CardioGenics Holdings Inc. (OTCQB:CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics testing market, announced today that Karim Murabet has been appointed as a director of the Company, effective January 12, 2015. Mr. Murabet will serve as an independent director.